In mismatch repair deficient recurrent endometrial cancer eligible for single agent PD-1 inhibitor, do you prefer pembrolizumab or dostarlimab and why?

In dMMR recurrent endometrial cancer eligible for single agent PD-1 inhibitor, do you prefer pembrolizumab or dostarlimab and why? (select the agent and select your rationale)

• No preference
• Pembrolizumab
• Dostarlimab
• Adverse event profile
• Dosing schedule
• Increased experience/familiarity
• Favorable cost profile
• Other